Fig. 3

Neonatally initiated Il-10 or sIl10R expression does not alter tau pathology in rTg4510 mice. Neonatal rTg4510 mice were injected with AAV-Il10 in the cerebral ventricles and brains were harvested at 8 months of age. Naïve age-matched mice were used as control. A. Whole brain weights were collected immediately after euthanasia. B-E. Representative sections from male and female mice showing Iba1 (B), and GFAP (D) staining in mice brain. Scale, 50 μm (inset), 200 μm (main panel). Panel insets are zoomed depictions from cortex. Immunoreactivity was quantified using ImageScope analysis of antibody staining intensity from cortex and hippocampus and graphed (C, E). F-I. Analysis of tau pathology in Il10 expressing 8-month old rTg4510 mice. Representative sections showing PHF1 (F-G) and Alz50 (H-I) immunostaining along with corresponding immunoreactivity burden (G, I) from Il10 expressing rTg4510 mice and controls. Immunoreactivity was quantified using ImageScope analysis from cortex and hippocampus and graphed. Scale, 50 μm. n = 7–8 mice/group (red, female mice; blue, male mice). J-Q. Neonatal rTg4510 mice received AAV-sIl10R in their cerebral ventricles and brains were harvested at 4 months (J, K, N, O) or 6 months (L, M, P, Q) of age. Naïve age-matched mice were used as control. Representative sections showing AT8 (J-M) and Alz50 (N-Q) along with corresponding immunoreactivity burden (K, M, O, Q) from sIl10R expressing rTg4510 mice and controls. Immunoreactivity burden was quantified using ImageScope analysis from cortex and hippocampus and graphed. Scale, 50 μm. n = 6–11 mice/group (red, female mice; blue, male mice)